DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Francis Tally and the discovery and development of tigecycline: a personal reminiscence.

Author(s): Projan SJ

Affiliation(s): Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, USA. steven.projan@novartis.com

Publication date & source: 2010-01-01, Clin Infect Dis., 50 Suppl 1:S24-5.

Publication type: Biography; Historical Article; Research Support, Non-U.S. Gov't; Tally F

For Francis Tally, both medicine and science were highly personal undertakings. Tally thought that emotional engagement was important in one's work and one's life, which were inseparable in his case. Indeed, Tally materially participated in no fewer than 4 programs that resulted in the approval and commercialization of novel antibiotics. These included piperacillin-tazobactam (which is currently the injectable antibiotic with the largest volume of sales worldwide) and daptomycin. This article focuses on the discovery and development of tigecycline.

Page last updated: 2010-10-05

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017